Eagle Pharmaceuticals Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Eagle Pharmaceuticals Inc은 수익성이 있나요?
Eagle Pharmaceuticals Inc에 부채가 있나요?
Eagle Pharmaceuticals Inc의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$0.25
시가
$0.25
일일 범위
$0.25 - $0.25
52주 범위
$0.1 - $3.87
거래량
2.2K
평균 거래량
3.8K
EPS(TTM)
0.92
배당수익률
--
시가총액
$3.2M
EGRX란 무엇인가요?
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.